M&A / Deals Novartis and Chai Discovery collaborate on antibody identification Pharmaceutical TechnologyNovartis has entered a collaboration with Chai Discovery to advance the use of AI in the identification of therapeutic antibodies.Read full story pharminent July 14, 2026 (Last updated: July 14, 2026) Pharmaceutical Technology Novartis has entered a collaboration with Chai Discovery to advance the use of AI in the identification of therapeutic antibodies. Read full story Post navigation Previous: FDA clears at-home start dose for Alzheimer’s drug LeqembiNext: AstraZeneca takes another China trip, picking Dizal’s lung cancer drug for up to $1.5B Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026